Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

December

7

electroCore Announces Issuance of Two New U.S. Patents

Expansion of patent portfolio allows exploration of the role of nVNS beyond migraine and...

14

electroCore Provides Select Third Quarter 2022 Financial Guidance

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021...

12

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)

nVNS reduces symptoms of PTSD by 31% in sham-controlled study ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE...

11

electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store

E-Commerce platform allows patients to obtain prescriptions, purchase nVNS devices, and receive training ROCKAWAY,...

20

electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England

Peer-reviewed paper appears in the British Journal of Healthcare Management ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE)...

21

electroCore Announces Peter Cuneo as Board Chairman

ROCKAWAY, NJ, Sept. 20, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today...

5

electroCore Announces Second Quarter 2021 Financial Results

Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020...

16

electroCore to Join Russell Microcap® Index

Effective after the open of trading on June 28, 2021 ROCKAWAY, NJ, June 16, 2021 (GLOBE...

6

electroCore Announces First Quarter 2021 Financial Results

Record first quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020...